The verluma market research report is one of a series of new reports that provides verluma market statistics, including the verluma industry global market size, regional shares, competitors with the verluma market share, detailed verluma market segments, market trends, and opportunities, and any further data you may need to thrive in the verluma industry. This verluma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the rising number of clinical trials, expansion of insurance coverage, increasing incidence of mental health disorders, growing prevalence of neurological disorders, and expansion of telemedicine services. Major trends in the forecast period include the integration of AI and digital health platforms, advancements in drug delivery technologies, advancements in genetic research, technological advancements in drug formulation, and the development of long-acting formulations.
The increasing incidence of cancer is anticipated to drive the growth of the Verluma market. Cancer is a collection of diseases marked by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and spread to other parts of the body via the blood and lymphatic systems. The rising number of cancer cases is attributed to factors such as aging populations, lifestyle changes, and the globalization of risk factors. Verluma is a therapeutic device that employs advanced technology, such as electromagnetic fields or other non-invasive methods, to potentially aid in cancer treatment by targeting and disrupting cancer cell growth, promoting healing, and enhancing the body’s response to other therapies. For example, in 2024, the American Cancer Society projects that over 2 million new cancer cases will be diagnosed in the U.S., up from 1.9 million in 2023. This growing incidence of cancer is fueling the expansion of the Verluma market.
The increasing demand for diagnostic imaging procedures is also expected to drive growth in the Verluma market. Diagnostic imaging encompasses various medical techniques used to create visual representations of the inside of the body for clinical evaluation and medical intervention. The demand for these procedures is growing due to the rising prevalence of chronic diseases, a stronger emphasis on early detection and preventive healthcare, and improved access to healthcare. Verluma enhances these imaging procedures by improving image quality through advanced algorithms, which allows for more precise detection and analysis of medical conditions, ultimately improving patient outcomes. For instance, the National Health Service reported that in the year ending March 2023, England conducted 45 million imaging tests, marking a 2.2% increase from 44 million in 2022. As a result, the growing demand for diagnostic imaging is supporting the growth of the Verluma market.
The rise in healthcare expenditure is expected to further propel the growth of the Verluma market. Healthcare expenditure refers to the total amount of money spent on healthcare services, including medical treatments, hospital care, pharmaceuticals, infrastructure, and preventive care. The increase in healthcare spending is driven by factors such as an aging population, the rising incidence of chronic diseases, technological advancements, and the higher demand for healthcare services. Increased healthcare spending benefits Verluma by boosting the demand for advanced healthcare technologies, including those that improve patient outcomes and operational efficiency. For example, in December 2023, the Centers for Medicare & Medicaid Services reported that U.S. healthcare spending grew by 4.1% to reach $4.5 trillion in 2022, following a 3.2% rise in 2021. Consequently, the rise in healthcare expenditure is contributing to the growth of the Verluma market.
The countries covered in the verluma market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Verluma is a radiolabeled monoclonal antibody fragment used in nuclear medicine to target carcinoembryonic antigen (CEA), a protein commonly overexpressed in cancerous tumors. It assists in detecting and staging cancers, such as colorectal cancer, by binding to CEA-expressing tumor cells, enabling visualization through imaging techniques such as SPECT.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Verluma are both cancer-related and non-cancer conditions. Cancer refers to a group of diseases characterized by uncontrolled cell growth and the potential to spread, with treatments such as Verluma specifically targeting cancer cells to slow tumor growth and improve patient outcomes. Verluma is distributed through various channels, including hospital pharmacies and online pharmacies, and caters to a range of end users, including adults and geriatric patients.
The verluma market consists of sales of verluma injection and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the rising number of clinical trials, expansion of insurance coverage, increasing incidence of mental health disorders, growing prevalence of neurological disorders, and expansion of telemedicine services. Major trends in the forecast period include the integration of AI and digital health platforms, advancements in drug delivery technologies, advancements in genetic research, technological advancements in drug formulation, and the development of long-acting formulations.
The increasing incidence of cancer is anticipated to drive the growth of the Verluma market. Cancer is a collection of diseases marked by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and spread to other parts of the body via the blood and lymphatic systems. The rising number of cancer cases is attributed to factors such as aging populations, lifestyle changes, and the globalization of risk factors. Verluma is a therapeutic device that employs advanced technology, such as electromagnetic fields or other non-invasive methods, to potentially aid in cancer treatment by targeting and disrupting cancer cell growth, promoting healing, and enhancing the body’s response to other therapies. For example, in 2024, the American Cancer Society projects that over 2 million new cancer cases will be diagnosed in the U.S., up from 1.9 million in 2023. This growing incidence of cancer is fueling the expansion of the Verluma market.
The increasing demand for diagnostic imaging procedures is also expected to drive growth in the Verluma market. Diagnostic imaging encompasses various medical techniques used to create visual representations of the inside of the body for clinical evaluation and medical intervention. The demand for these procedures is growing due to the rising prevalence of chronic diseases, a stronger emphasis on early detection and preventive healthcare, and improved access to healthcare. Verluma enhances these imaging procedures by improving image quality through advanced algorithms, which allows for more precise detection and analysis of medical conditions, ultimately improving patient outcomes. For instance, the National Health Service reported that in the year ending March 2023, England conducted 45 million imaging tests, marking a 2.2% increase from 44 million in 2022. As a result, the growing demand for diagnostic imaging is supporting the growth of the Verluma market.
The rise in healthcare expenditure is expected to further propel the growth of the Verluma market. Healthcare expenditure refers to the total amount of money spent on healthcare services, including medical treatments, hospital care, pharmaceuticals, infrastructure, and preventive care. The increase in healthcare spending is driven by factors such as an aging population, the rising incidence of chronic diseases, technological advancements, and the higher demand for healthcare services. Increased healthcare spending benefits Verluma by boosting the demand for advanced healthcare technologies, including those that improve patient outcomes and operational efficiency. For example, in December 2023, the Centers for Medicare & Medicaid Services reported that U.S. healthcare spending grew by 4.1% to reach $4.5 trillion in 2022, following a 3.2% rise in 2021. Consequently, the rise in healthcare expenditure is contributing to the growth of the Verluma market.
The key company operating in the verluma market is Boehringer Ingelheim International GmbH
North America was the largest region in the verluma market in 2024. The regions covered in verluma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the verluma market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Verluma is a radiolabeled monoclonal antibody fragment used in nuclear medicine to target carcinoembryonic antigen (CEA), a protein commonly overexpressed in cancerous tumors. It assists in detecting and staging cancers, such as colorectal cancer, by binding to CEA-expressing tumor cells, enabling visualization through imaging techniques such as SPECT.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Verluma are both cancer-related and non-cancer conditions. Cancer refers to a group of diseases characterized by uncontrolled cell growth and the potential to spread, with treatments such as Verluma specifically targeting cancer cells to slow tumor growth and improve patient outcomes. Verluma is distributed through various channels, including hospital pharmacies and online pharmacies, and caters to a range of end users, including adults and geriatric patients.
The verluma market consists of sales of verluma injection and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Verluma Market Characteristics4. Verluma Market Trends And Strategies5. Verluma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Verluma Pricing Analysis & Forecasts30. Global Verluma Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Verluma Market32. Recent Developments In The Verluma Market
3. Verluma Market Biologic Drug Characteristics
6. Global Verluma Growth Analysis And Strategic Analysis Framework
8. Verluma Market Segmentation
9. Global Verluma Epidemiology Of Clinical Indications
10. Verluma Market Regional And Country Analysis
11. Asia-Pacific Verluma Market
12. China Verluma Market
13. India Verluma Market
14. Japan Verluma Market
15. Australia Verluma Market
16. South Korea Verluma Market
17. Western Europe Verluma Market
18. UK Verluma Market
19. Germany Verluma Market
20. France Verluma Market
21. Eastern Europe Verluma Market
22. North America Verluma Market
23. USA Verluma Market
24. Canada Verluma Market
25. South America Verluma Market
26. Middle East Verluma Market
27. Africa Verluma Market
28. Verluma Market Competitive Landscape And Company Profiles
29. Global Verluma Market Pipeline Analysis
33. Verluma Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Verluma Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on verluma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for verluma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The verluma market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Cancer; Non-Cancer2) By Distribution Channel: Hospital Pharmacies; Online Pharmacies
3) By End User: Adult; Geriatric
Key Companies Profiled: Boehringer Ingelheim International GmbH
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Boehringer Ingelheim International GmbH
